Merck is trading at $151.09 (+11.74%) after Merck and Moderna reported positive Phase 3 results for personalized mRNA cancer vaccine intismeran combined with Keytruda.
- The treatment met primary recurrence-free-survival and secondary distant-metastasis-free-survival endpoints in high-risk melanoma patients.
- Results support expectations for a potentially important new oncology franchise.
- Multiple major outlets linked the rally to the announcement, with healthcare sector strength providing additional support.